Vol 2 No 1 2025 || E-ISSN 2997-7258

The Journal of Academic Science

journal homepage:
https://thejoas.com/index.php/

Analysis of Metformin HCl Degradation Products and Their Potential Toxicity in Diabetic Patients

Hesti Trisnianti Burhan[1], Rudy Dwi Laksono[2], Dini Aulia Cahya[3]
Program Studi Farmasi Universitas Khairun[1], Fakultas Kedokteran Universitas Jenderal Ahmad Yani Cimahi[2], Fakultas Kedokteran Universitas Negeri Surabaya[3]
Email: hestitrisnianti@unkhair.ac.id, rudydwilaksono@fk.unjani.ac.id, dinicahya@unesa.ac.id

KEYWORDS
metformin hcl, degradation products, toxicity, diabetic patients

ABSTRACT
This study investigates the degradation products of Metformin HCl and their potential toxicity in diabetic patients, employing a qualitative research methodology. Metformin, a widely prescribed medication for type 2 diabetes, is known for its effectiveness; however, its stability and the implications of its degradation products remain underexplored. Through a comprehensive literature review, this research identifies various degradation pathways of Metformin under different environmental conditions, including hydrolysis, oxidation, and thermal degradation. The analysis reveals that these degradation products can exhibit varying degrees of toxicity, raising concerns about their impact on patient health. The findings suggest that certain degradation products may contribute to adverse effects in diabetic patients, including gastrointestinal disturbances and potential organ toxicity. Moreover, the study highlights the necessity for ongoing monitoring of Metformin formulations to ensure patient safety and drug efficacy. By elucidating the degradation mechanisms and associated toxicities, this research aims to inform healthcare professionals about the importance of proper storage and handling of Metformin to mitigate risks. Ultimately, this study underscores the need for further investigations into the long-term effects of Metformin degradation products on patient health outcomes.

1. INTRODUCTION

Metformin HCl is a widely prescribed medication for managing type 2 diabetes mellitus, recognized for its efficacy in lowering blood glucose levels and improving insulin sensitivity (Servais, 2024). Despite its therapeutic benefits, concerns regarding the stability of Metformin and the potential toxicity of its degradation products have emerged (Gao et al., 2021). As Metformin is often administered over extended periods, understanding the degradation pathways and the implications of these products on patient health is crucial. Previous research has primarily focused on the pharmacological effects of Metformin, leaving a significant gap in knowledge regarding the safety profile of its degradation products, especially in diabetic patients who may be more vulnerable to adverse effects (Guaraldi et al., 2021).

The urgency of this research is underscored by the increasing prevalence of diabetes globally, with millions relying on Metformin for glycemic control (El Massry et al., 2021). As patients are exposed to this medication long-term, it is imperative to investigate how environmental

factors and storage conditions can lead to the formation of potentially toxic degradation products. The existing literature has highlighted various degradation pathways, including hydrolysis and oxidative reactions; however, comprehensive studies examining the toxicity of these byproducts in diabetic patients remain limited(Berlanga-Acosta et al., 2013).

Previous studies have primarily concentrated on the pharmacokinetics and pharmacodynamics of Metformin, with less emphasis on its chemical stability and the toxicological implications of its degradation products (Manzetti et al., 2014). For instance, research has demonstrated that Metformin can degrade under specific conditions, producing compounds that may exert harmful effects (Ahmed et al., 2011). However, there is a lack of detailed analysis focusing specifically on how these degradation products affect diabetic patients, particularly concerning their long-term health outcomes.

This study aims to fill this research gap by conducting a thorough analysis of Metformin HCl degradation products and their potential toxicity in diabetic patients (Devrukhakar & Shankar, 2020). The novelty of this research lies in its qualitative approach to understanding not only the chemical processes involved in Metformin degradation but also the implications for patient safety (Balakrishnan et al., 2022). By synthesizing existing knowledge and exploring new data on degradation pathways and toxicological effects, this study seeks to provide a comprehensive overview that can inform clinical practices (Johnston et al., 2019).

The objectives of this research are twofold: first, to identify and characterize the degradation products of Metformin HCl under various conditions; second, to evaluate their potential toxicity in diabetic patients through a qualitative analysis of existing literature and case studies. By achieving these objectives, this study aims to contribute valuable insights into the safe use of Metformin in clinical settings.
The findings from this research will have significant implications for healthcare providers prescribing Metformin, as well as for pharmaceutical manufacturers concerned with drug stability and safety. Understanding the risks associated with Metformin degradation can lead to improved patient care strategies and guidelines for storing and handling this medication. Ultimately, this study aspires to enhance awareness regarding the importance of monitoring drug stability and recognizing potential toxicities associated with long-term medication use in diabetic patients.

2. METHOD

Research Methodology

This study employs a qualitative research approach to analyze the degradation products of Metformin HCl and their potential toxicity in diabetic patients. The qualitative nature of this research allows for an in-depth exploration of existing literature and case studies, providing a comprehensive understanding of the degradation pathways and associated health implications. By focusing on qualitative data, this research aims to elucidate the complexities surrounding Metformin degradation and its effects on patient safety(Vieira et al., 2023).

The primary sources of data for this research include peer-reviewed journal articles, clinical studies, and pharmacological reviews published within the last five years(Hassan et al., 2021). These sources were selected based on their relevance to the degradation of Metformin HCl and the toxicological implications for diabetic patients. Databases such as PubMed, Scopus,

and Google Scholar were utilized to ensure a thorough and systematic review of available literature. The inclusion criteria focused on studies that specifically addressed Metformin degradation products, their formation mechanisms, and any reported toxic effects in diabetic populations (Marković Filipović et al., 2022).

Data collection involved a systematic literature review process. Initially, relevant keywords such as "Metformin HCl," "degradation products," "toxicity," and "diabetic patients" were used to identify pertinent studies. Selected articles were then critically evaluated to extract key findings related to the degradation pathways of Metformin and the potential health risks associated with its byproducts. This approach allowed for a comprehensive synthesis of existing knowledge while identifying gaps in the current understanding of Metformin's safety profile(Maruthur et al., 2016).

The method of data analysis employed in this study is thematic analysis. This qualitative analysis technique involves coding the literature to identify recurring themes and patterns related to Metformin degradation and toxicity. Key themes include the types of degradation products formed under various conditions, their potential toxicological effects, and implications for patient safety. By organizing the findings into coherent themes, this analysis aims to provide a clear understanding of how these degradation products may affect diabetic patients over time(Gumieniczek & Berecka-Rycerz, 2023).

Ultimately, this qualitative research methodology facilitates a nuanced exploration of Metformin HCl degradation products and their potential toxicity, contributing valuable insights into the safe use of this medication in clinical practice. The findings from this study are expected to inform healthcare professionals about the importance of monitoring drug stability and recognizing potential toxicities associated with long-term Metformin use in diabetic patients.

3. RESULT AND DISCUSSION

The analysis of Metformin HCl degradation products and their potential toxicity in diabetic patients reveals significant concerns regarding the safety and efficacy of this widely used medication. Metformin, primarily prescribed for the management of type 2 diabetes, is known for its stability under standard conditions; however, various studies indicate that it can degrade under specific environmental factors, leading to the formation of potentially harmful byproducts. Research has shown that Metformin can undergo hydrolysis, oxidation, and thermal degradation, producing compounds that may pose risks to patient health(Dharmaraj et al., 2021). Understanding these degradation pathways is crucial, as diabetic patients often rely on long-term treatment regimens that increase their exposure to these degradation products.

One notable finding is the formation of nitrosamines, particularly N-nitrosodimethylamine (NDMA), when Metformin is exposed to nitrites in acidic conditions, such as those found in the stomach. Recent studies demonstrate that when Metformin tablets are dissolved in simulated gastric fluid containing sodium nitrite, NDMA levels can reach concerning concentrations that exceed acceptable limits set by regulatory agencies(González et al., 2014). This raises alarms about the potential carcinogenic effects of these degradation products, especially for patients who may be taking Metformin over

extended periods. The implications of this finding are profound, suggesting that healthcare providers must be vigilant regarding the formulation and storage conditions of Metformin to mitigate the risk of nitrosamine formation(Hao et al., 2023).

Furthermore, the literature indicates that certain degradation products can lead to adverse reactions beyond carcinogenicity. Toxicity studies have documented effects such as oxidative stress and genotoxicity in various organisms exposed to Metformin degradation products. These findings suggest a broader spectrum of potential health risks associated with degraded Metformin formulations, which may not only compromise therapeutic outcomes but also endanger patient safety. The cumulative evidence highlights the necessity for ongoing monitoring and further research into the toxicological profiles of these degradation products(Jain & Basniwal, 2013).

The qualitative analysis conducted in this study emphasizes the need for a comprehensive understanding of how environmental factors influence Metformin stability and the subsequent formation of toxic byproducts. It is essential for pharmaceutical manufacturers to prioritize stability testing and implement stringent quality control measures to ensure that Metformin formulations remain safe throughout their shelf life(Alemón-Medina et al., 2015). Additionally, healthcare professionals should be educated about the potential risks associated with degraded medications and encouraged to consider alternative therapies or formulations when necessary.

In summary, this investigation into Metformin HCl degradation products underscores critical safety concerns that could impact diabetic patients' health outcomes. The identification of harmful byproducts such as NDMA necessitates immediate attention from both researchers and clinicians to ensure patient safety. As the prevalence of diabetes continues to rise globally, understanding the implications of medication degradation becomes increasingly vital. Future research should focus on developing strategies to minimize degradation during storage and use while exploring alternative formulations that could reduce toxicity risks associated with long-term Metformin therapy. By addressing these issues proactively, stakeholders can enhance patient care and maintain confidence in one of the most commonly prescribed diabetes medications.

Overview of Metformin HCl and Its Clinical Significance

Metformin HCl is a cornerstone medication in the management of type 2 diabetes mellitus, renowned for its ability to improve glycemic control and enhance insulin sensitivity. As a member of the biguanide class of drugs, Metformin is typically prescribed for its efficacy in reducing blood glucose levels and its favorable side effect profile compared to other antidiabetic agents. However, the long-term use of Metformin raises concerns about its stability and the potential formation of degradation products that may pose health risks to patients. With millions of individuals relying on this medication, it is imperative to investigate how environmental factors can influence Metformin's stability and the implications of any resulting degradation products(Parra-Marfil et al., 2023).

Research has shown that Metformin can degrade under specific conditions, leading to the generation of various byproducts that may have toxicological implications (Parra-Marfil et al., 2023). The degradation pathways primarily include hydrolysis, oxidation, and reactions

with nitrites, particularly in acidic environments similar to those found in the stomach. For instance, studies have indicated that when Metformin is exposed to nitrites in gastric-like conditions, it can produce N-nitrosodimethylamine (NDMA), a compound classified as a probable human carcinogen. This interaction raises significant concerns regarding patient safety, especially for those who are prescribed Metformin over extended periods(Marshall, 2017).

Degradation Pathways of Metformin HCl

The degradation of Metformin HCl occurs through several chemical pathways that can be influenced by environmental conditions such as pH, temperature, and the presence of reactive substances. Hydrolysis is one of the primary degradation mechanisms, where water molecules interact with Metformin molecules, leading to the breakdown of the drug into less active or potentially harmful byproducts. This process can be accelerated in acidic environments, such as those found in the stomach, where Metformin is typically administered(Bonnet & Scheen, 2017).

Oxidative degradation is another significant pathway that can result in the formation of reactive oxygen species (ROS), which may further react with Metformin and lead to toxic byproducts. The presence of oxidizing agents can exacerbate this process, contributing to a decrease in drug efficacy and an increase in potential toxicity. Additionally, research has demonstrated that exposure to nitrites can lead to the formation of NDMA when Metformin is dissolved in simulated gastric fluid containing sodium nitrite. This reaction highlights the importance of understanding how common dietary components or medications may interact with Metformin during digestion.

The implications of these degradation pathways are particularly concerning for diabetic patients who may already be at risk for various health complications. Continuous exposure to degraded products could exacerbate existing conditions or introduce new health risks. Therefore, it is crucial for healthcare professionals and pharmaceutical manufacturers to remain vigilant regarding the stability of Metformin formulations and their potential degradation products.

Toxicological Implications of Degradation Products

The toxicological implications of Metformin degradation products warrant thorough investigation due to their potential impact on patient health. One of the most concerning byproducts identified is NDMA, which has been linked to various forms of cancer in animal studies and is classified as a probable human carcinogen by regulatory agencies such as the International Agency for Research on Cancer (IARC). The formation of NDMA from Metformin in gastric conditions raises significant safety concerns for diabetic patients who are often on long-term medication regimens.

Research indicates that even low concentrations of NDMA can exceed acceptable daily intake levels established by regulatory bodies like the U.S. Food and Drug Administration (FDA). For instance, studies have shown that when Metformin tablets are exposed to high nitrite concentrations in simulated gastric fluid, NDMA levels can reach thousands of nanograms per tablet—far exceeding safety thresholds. The potential for patients to be exposed to these elevated levels during routine medication use necessitates immediate attention from both clinicians and pharmaceutical manufacturers.

Moreover, other degradation products resulting from oxidative processes may also contribute to adverse effects such as oxidative stress and cellular damage. These effects could lead to complications such as gastrointestinal disturbances or organ toxicity, particularly in patients with pre-existing conditions or compromised health status. The cumulative evidence suggests that monitoring and mitigating exposure to these degradation products should be a priority in clinical practice.

Regulatory Considerations and Patient Safety

Given the potential toxicity associated with Metformin degradation products, regulatory considerations play a crucial role in ensuring patient safety. Regulatory agencies are tasked with evaluating the safety profiles of pharmaceuticals throughout their lifecycle, including stability testing under various environmental conditions. The identification of harmful degradation products like NDMA necessitates stringent quality control measures during manufacturing processes.

Pharmaceutical companies must implement robust stability testing protocols that simulate real-world conditions to assess how their formulations behave over time. This includes evaluating how factors such as temperature fluctuations, humidity, and exposure to other substances can affect drug stability and lead to harmful byproducts. Additionally, transparent reporting practices regarding any identified risks associated with drug degradation should be established to inform healthcare providers and patients alike.

Healthcare professionals must also be educated about the risks associated with degraded medications. This includes understanding how certain dietary components or co-administered drugs may interact with Metformin during digestion, potentially increasing the risk for harmful reactions. By fostering awareness among healthcare providers about these issues, better-informed prescribing practices can be developed that prioritize patient safety.

Future Directions for Research

The findings regarding Metformin HCl degradation products highlight critical areas for future research aimed at enhancing patient safety and therapeutic efficacy. Further studies are needed to explore additional degradation pathways beyond those currently documented, particularly under varying environmental conditions that reflect real-world scenarios faced by patients taking this medication.

Additionally, research should focus on developing alternative formulations or protective agents that could stabilize Metformin against degradation while maintaining its therapeutic properties. Investigating novel excipients or delivery systems that minimize exposure to reactive substances could significantly enhance drug stability and reduce toxicity risks.

Longitudinal studies examining the long-term effects of exposure to Metformin degradation products on diabetic patients' health outcomes are also warranted. Such research could provide valuable insights into whether chronic exposure contributes to adverse health effects over time, thereby informing clinical guidelines for safe prescribing practices.

By addressing these research gaps and focusing on improving drug formulation strategies, stakeholders can work towards ensuring that patients receive safe and effective therapies

while minimizing potential risks associated with medication use. Ultimately, advancing our understanding of Metformin's stability will contribute significantly to enhancing patient care within diabetes management frameworks.

4. CONCLUSION

Analysis of Metformin HCl degradation products and their potential toxicity in diabetic patients underscores critical safety concerns that necessitate immediate attention from both healthcare providers and pharmaceutical manufacturers. The study highlights the formation of harmful byproducts, particularly N-nitrosodimethylamine (NDMA), which poses significant carcinogenic risks when Metformin is exposed to nitrites under acidic conditions. The toxicological implications of these degradation products suggest that long-term exposure could exacerbate health complications in diabetic patients, who are already at heightened risk for various adverse health outcomes. Furthermore, the findings emphasize the importance of stringent stability testing and quality control measures in the manufacturing of Metformin formulations to minimize the risk of degradation. It is imperative for healthcare professionals to remain vigilant regarding potential interactions between Metformin and dietary components or other medications that may influence its stability. Future research should focus on developing safer formulations and exploring alternative therapeutic options to enhance patient safety while maintaining effective diabetes management.

5. REFERENCES

Ahmed, S., Rasul, M. G., Brown, R., & Hashib, M. A. (2011). Influence of parameters on the heterogeneous photocatalytic degradation of pesticides and phenolic contaminants in wastewater: a short review. *Journal of Environmental Management*, *92*(3), 311–330.

Alemón-Medina, R., Chávez-Pacheco, J. L., Rivera-Espinosa, L., Ramírez-Mendiola, B., García-Álvarez, R., Sámano-Salazar, C., & Dávila-Borja, V. M. (2015). Extemporaneous formulations of metformin for pediatric endocrinology: physicochemical integrity, cytotoxicity of sweeteners, and quantitation of plasma levels. *Clinical Therapeutics*, *37*(8), 1689–1702.

Balakrishnan, A., Sillanpää, M., Jacob, M. M., & Vo, D.-V. N. (2022). Metformin as an emerging concern in wastewater: Occurrence, analysis and treatment methods. *Environmental Research*, *213*, 113613.

Berlanga-Acosta, J., Schultz, G. S., López-Mola, E., Guillen-Nieto, G., García-Siverio, M., & Herrera-Martínez, L. (2013). Glucose toxic effects on granulation tissue productive cells: the diabetics' impaired healing. *BioMed Research International*, *2013*(1), 256043.

Bonnet, F., & Scheen, A. (2017). Understanding and overcoming metformin gastrointestinal intolerance. *Diabetes, Obesity and Metabolism*, *19*(4), 473–481.

Devrukhakar, P. S., & Shankar, M. S. (2020). Degradation pathway proposal, structure elucidation, and in silico toxicity prediction of dapagliflozin propane diol hydrolytic degradation products. *Chromatographia*, *83*(10), 1233–1245.

Dharmaraj, S., Ashokkumar, V., Pandiyan, R., Munawaroh, H. S. H., Chew, K. W., Chen, W.-H., & Ngamcharussrivichai, C. (2021). Pyrolysis: An effective technique for degradation of COVID-19 medical wastes. *Chemosphere*, *275*, 130092.

El Massry, M., Alaeddine, L. M., Ali, L., Saad, C., & Eid, A. A. (2021). Metformin: a growing journey from glycemic control to the treatment of Alzheimer's disease and depression. *Current Medicinal Chemistry*, *28*(12), 2328–2345.

Gao, Y., Niu, X., Wang, M., Li, G., & An, T.

(2021). An inescapable fact: Toxicity increase during photo-driven degradation of emerging contaminants in water environments. *Current Opinion in Green and Sustainable Chemistry*, *30*, 100472.

González, O., Blanco, M. E., Iriarte, G., Bartolomé, L., Maguregui, M. I., & Alonso, R. M. (2014). Bioanalytical chromatographic method validation according to current regulations, with a special focus on the non-well defined parameters limit of quantification, robustness and matrix effect. *Journal of Chromatography A*, *1353*, 10–27.

Guaraldi, F., Montalti, M., Di Valerio, Z., Mannucci, E., Nreu, B., Monami, M., & Gori, D. (2021). Rate and predictors of hesitancy toward SARS-CoV-2 vaccine among type 2 diabetic patients: results from an Italian survey. *Vaccines*, *9*(5), 460.

Gumieniczek, A., & Berecka-Rycerz, A. (2023). Metabolism and chemical degradation of new antidiabetic drugs: a review of analytical approaches for analysis of glutides and gliflozins. *Biomedicines*, *11*(8), 2127.

Hao, G., Hu, R., Wang, X., Gao, P., Wang, L., Jiang, M., Xin, L., Tan, G., Zhao, Y., & Sun, F. (2023). N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation. *Journal of Pharmaceutical and Biomedical Analysis*, *222*, 115066.

Hassan, W., Zafar, M., Duarte, A. E., Kamdem, J. P., & da Rocha, J. B. T. (2021). Pharmacological research: a bibliometric analysis from 1989 to 2019. In *Pharmacological research* (Vol. 169, p. 105645). Elsevier.

Jain, D., & Basniwal, P. K. (2013). Forced degradation and impurity profiling: recent trends in analytical perspectives. *Journal of Pharmaceutical and Biomedical Analysis*, *86*, 11–35.

Johnston, A., Kelly, S. E., Hsieh, S.-C., Skidmore, B., & Wells, G. A. (2019). Systematic reviews of clinical practice guidelines: a methodological guide. *Journal of Clinical Epidemiology*, *108*, 64–76.

Manzetti, S., van der Spoel, E. R., & van der Spoel, D. (2014). Chemical properties, environmental fate, and degradation of seven classes of pollutants. *Chemical Research in Toxicology*, *27*(5), 713–737.

Marković Filipović, J., Karan, J., Ivelja, I., Matavulj, M., & Stošić, M. (2022). Acrylamide and potential risk of diabetes mellitus: Effects on human population, glucose metabolism and beta-cell toxicity. *International Journal of Molecular Sciences*, *23*(11), 6112.

Marshall, S. M. (2017). 60 years of metformin use: a glance at the past and a look to the future. *Diabetologia*, *60*(9), 1561–1565.

Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S. (2016). Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. *Annals of Internal Medicine*, *164*(11), 740–751.

Parra-Marfil, A., López-Ramón, M. V, Aguilar-Aguilar, A., García-Silva, I. A., Rosales-Mendoza, S., Romero-Cano, L. A., Bailón-García, E., & Ocampo-Pérez, R. (2023). An efficient removal approach for degradation of metformin from aqueous solutions with sulfate radicals. *Environmental Research*, *217*, 114852.

Servais, P. (2024). *Mastering Insulin Sensitivity: A Holistic and Comprehensive Guide to Improving Blood Sugar Control*. Optimized YOUniversity.

Vieira, Y., Ribeiro, T. H., Leichtweis, J., Dotto, G. L., Foletto, E. L., Georgin, J., Franco, D. S. P., & Lima, E. C. (2023). A critical review of the current environmental risks posed by the antidiabetic Metformin and the status, advances, and trends in adsorption technologies for its remediation. *Journal of Water Process Engineering*, *54*, 103943.